德康醫療 DXCM 深 滬
已收盤 02-06 16:00:00 美东时间
69.97
+0.080
+0.11%
華盛通- 最 高70.68
- 今 開70.57
- 成交量 365.99万股
- 最 低 68.68
- 昨 收 69.89
- 總市值 272.89亿
- 52周最高 93.25
- 市盈率 靜 49.14
- 換手率 0.94%
- 52周最低 54.11
- 委 比 85.73%
- 總股本 3.90亿
- 歷史最高 164.863
- 量 比 0.74
- 振 幅 2.86%
- 歷史最低 1.6875
- 每 手 1
- 風險率 9.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多秀洲以创新激活高质量发展新引擎
（来源：嘉兴日报） 转自：嘉兴日报 ■记者 戴瑞雪 通讯员 宋信详 “研发是企业的立身之本，我们每年都会拿出大额资金投入其中。”日前，麒盛科技研发总监...
02-02 07:44
Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
Senseonics' Eversense 365 CGM system, the first and only one-year implantable glucose monitor, receives CE Mark approval for EU commercialization. Offering continuous glucose monitoring for up to 365 days, it reduces sensor changes and enhances accuracy, improving diabetes management. Company plans expansion in Germany, Italy, Spain, and Sweden, aiming to boost revenue and address European diabetes patients.
01-29 21:01
DexCom Inc. to Announce Q4 and Fiscal Year 2025 Results
DexCom Inc. to Announce Q4 and Fiscal Year 2025 Results DexCom Inc. will release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will host a conference call to review the company’s performance at 4:30 p.m. Eastern Time on the sa
01-28 01:24
How Do Investors Really Feel About DexCom Inc?
DexCom Inc's (NYSE:DXCM) short interest as a percent of float has risen 9.95% s...
01-16 02:00
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
DexCom shares are trading higher after the company reported preliminary Q4 revenue results.
DexCom shares are trading higher after the company reported preliminary Q4 reve...
01-13 04:07
DexCom Reports Preliminary Q4 Revenue Of ~$1.260B, 2025 Revenue Of ~$4.662B
DexCom, Inc. (NASDAQ:DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the fourth quarter of
01-12 20:34
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Bernstein Maintains Outperform on DexCom, Raises Price Target to $86
Bernstein analyst Lee Hambright maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $84 to $86.
01-10 03:11
DexCom Announces Leadership Transition As Jake Leach Assumes Expanded Role As President and CEO
Mr. Leach begins his inaugural year as CEO with speaking engagements at CES 2026 and the 44th annual J.P. Morgan Healthcare ConferenceA completely reimagined Stelo app experience will launch this year, further advancing
01-07 22:09
